Effect of diacerein on insulin secretion and metabolic control in drug-naïve patients with type 2 diabetes: A randomized clinical trial

Diabetes Care

Volumn 34, Issue 7, 2011, Pages 1591-1594

  Ramos Zavala, Maria G ^a   González Ortiz, Manuel ^a,b   Martínez Abundis, Esperanza ^a,b   Robles Cervantes, José A ^a   González López, Roberto ^a   Santiago Hernández, Nestor J ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DIACEREIN; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ANTHRAQUINONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SOCIOECONOMICS; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; METABOLISM; MIDDLE AGED; OBESITY; SECRETION;

ADULT; ANTHRAQUINONES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054701972     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0357     Document Type: Article

References (20)

1. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009;58:2718-2725
2. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
3. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010;17:332-341
4. Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008;29:334-350 (Pubitemid 351679703)
5. Ortis F, Pirot P, Naamane N, et al. Induction of nuclear factor-kappaB and its down-stream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008;51:1213-1225
6. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006;1:CD005117
7. Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther 2008;10:R71
8. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner RdeL. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol 2008;8:782-791
9. González-Ortiz M, Martínez-Abundis E. Comparison of several formulas to assess insulin action in the fasting state with the hyperglycemic-hyperinsulinemic clamp technique in healthy individuals. Rev Invest Clin 2003;55:419-422 (Pubitemid 37461392)
10. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
11. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian Pediatr 1989;26:115-121
12. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526 (Pubitemid 46588416)
13. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-1668
14. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-1249
15. Martínez-Abundis E, Reynoso-von Drateln C, Hernández- Salazar E, González-OrtizM. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007;299:461-465 (Pubitemid 47546924)
16. Tran POT, Gleason CE, Robertson RP. Inhibition of interleukin-1b-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet β-cell function. Diabetes 2002;51:1772-1778 (Pubitemid 34564289)
17. González-Ortiz M, Pascoe-González S, Esperanzamartí nez-Abundis, Kam-Ramos AM, Hernández-Salazar E. Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects. Metab Syndr Relat Disord 2005;3:95-101 (Pubitemid 41269267)
18. González-Ortiz M, Hernández-Salazar E, Kam-Ramos AM, Martínez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract 2007;75:115-118 (Pubitemid 44873140)
19. Wang AP, Li X, Zheng Y, et al. Thiazolidinediones protect mouse pancreatic β-cells directly from cytokine-induced cytotoxicity through PPARγ-dependent mechanisms. Acta Diabetol. 10 December 2010 [Epub ahead of print]
20. Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18: 289-296